Loading clinical trials...

ACTIVE_NOT_RECRUITING

Plasmafit® Revision Structan® Hip Endoprosthesis Cup

Prospective, Multi-centric, Comparative, Long-term Clinical Follow-Up Study for the Evidence of Safety and Performance Indicators of the Plasmafit® Revision Structan® Hip Endoprosthesis Cup

NCT04255966•Aesculap AG

View on ClinicalTrials.gov

Summary

The aim of this observational study is to collect clinical and radiological results of the new Plasmafit® Revision Structan® Hip Endoprosthesis Cup in a standard patient population and when used in routine clinical practice.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Indication for the cementless Plasmafit® Revision Structan® Hip Endoprosthesis Cup (primary and revision cases, with bone conditions typically demanding a press-fit revision cup)
•Written informed consent
•Cases where a press-fit cup fixation is possible

Exclusion Criteria

•Patients \< 18 years
•Pregnant patients
•Patients not able to comply with the study demands, i.e. follow-up visits (mentally or physically)
•Patient has an infection in the hip joint region

Locations (4)

Orthopädische Klinik König-Ludwig-Haus

Würzburg, Bavaria, Germany

Herzogin Elisabeth Hospital

Braunschweig, Niedersachse, Germany

Gemeinschaftskrankenhaus Bonn

Bonn, North Rhine-Westphalia, Germany

Universitätsklinikum des Saarlandes

Homburg, Saarland, Germany

Key Dates

Start Date

April 12, 2021

Primary Completion Date

August 16, 2023

Completion Date

June 1, 2027

Last Updated

April 29, 2025

Enrollment

ACTUAL participants

Conditions

OsteolysisArthroplasty ComplicationsInstability of Prosthetic JointDegenerative OsteoarthritisRheumatic ArthritisFractures, HipFemoral Head Avascular NecrosisProsthesis Failure

Interventions

Plasmafit® Revision Structan®

DEVICE

Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN)

NCT06527664

Bone LossHip Prosthesis Infection+1 more

View study

RECRUITINGNA

The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty

NCT05216666

Hip OsteoarthritisMuscle Weakness+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Plasmafit® Revision Structan® Hip Endoprosthesis Cup

Inclusion Criteria

Exclusion Criteria

Innovative Technologies for Salvage Procedures of Failed Treatments of Osteoarthritis: Biomimetics Solutions (CustomPN)

The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty

Does Vessel-sparing Surgery in Anterior Approach Total Hip Arthroplasty Change Clinical Outcome?

General vs Spinal Anesthesia for Total Joint Arthroplasty-Anterior Approach: A Single-Institution Observational Study

Blood Loss Assessment in the Limited Application of Tourniquet During Primary Unilateral TKA

Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty